Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.

Molecular therapy : the journal of the American Society of Gene Therapy·2022
Same author

Topics in AAV integration come front and center at ASGCT AAV Integration Roundtable.

Molecular therapy : the journal of the American Society of Gene Therapy·2021
Same author

Targeting Root Cause by Systemic scAAV9-h<i>IDS</i> Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice.

Molecular therapy. Methods & clinical development·2018
Same author

Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy.

Human gene therapy. Clinical development·2017
Same author

Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.

Metabolic brain disease·2017
Same author

Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting.

Molecular therapy. Methods & clinical development·2017
Same journal

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Long-term functional synaptic integration of genome-edited retinal organoids in a primate model of macular degeneration.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Nox1/4 inhibitor Setanaxib treatment ameliorates cardiac function in mouse models of Duchenne Muscular Dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

HSP90α-USP7-DNMT1 Axis Drives Hepatocellular Carcinoma Recurrence After Microwave Ablation by Disrupting ACSS3-Mediated Propionate Metabolism.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Self-complementary AAV vectors; advances and applications.

Douglas M McCarty1

  • 1Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio 43205, USA. Douglas.McCarty@nationwidechildrens.org

Molecular Therapy : the Journal of the American Society of Gene Therapy
|August 7, 2008
PubMed
Summary
This summary is machine-generated.

Self-complementary adeno-associated virus (scAAV) vectors enhance gene delivery efficiency by packaging a double-stranded DNA genome, bypassing cellular DNA replication steps. This improved transduction efficiency is crucial for gene therapy applications across various tissues.

More Related Videos

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors
09:21

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants
09:20

Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants

Published on: October 18, 2022

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
09:12

Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol

Published on: April 5, 2024

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Virology

Background:

  • Recombinant adeno-associated virus (rAAV) vectors show promise in clinical gene therapy.
  • Current rAAV vector efficiency is limited by the need for single-stranded DNA (ssDNA) to double-stranded DNA (dsDNA) conversion for gene expression.

Purpose of the Study:

  • To review the construction, properties, and efficiency of self-complementary AAV (scAAV) vectors.
  • To explore the basis for variable scAAV vector responses in different tissues.

Main Methods:

  • Utilizes self-complementary vector design, packaging an inverted repeat genome.
  • Facilitates direct conversion to dsDNA without cellular DNA synthesis or intermolecular base-pairing.

Main Results:

  • scAAV vectors significantly increase transduction efficiency compared to standard rAAV vectors.
  • Efficiency gains vary depending on tissue type, cell, and administration route.
  • Coding capacity is reduced by half, suitable for small genes (<55 kd) or RNA-based therapies.

Conclusions:

  • scAAV vectors offer a more efficient gene delivery platform by overcoming ssDNA to dsDNA conversion limitations.
  • Understanding tissue-specific responses is key to optimizing scAAV vector applications in gene therapy.